Vanguard Asset Management’s Rapport Therapeutics RAPP Stock Holding History
Bought
Maintained
Sold
Other funds holding RAPP
Vanguard Asset Management's RAPP Position: Q3 2026 in Review
Vanguard Asset Management increased its Rapport Therapeutics (RAPP) stake by 17% in Q3 2026, buying an estimated $135K and bringing the position to 21,659 shares worth $728K. The position accounts for ﹤0.01% of the portfolio, ranked #2006.
Vanguard Asset Management first reported a position in RAPP in Q1 2026 and has held it in 3 quarters since. The position peaked at $772K in Q2 2026. 168 funds tracked by Wall St. Rank hold RAPP as of Q3 2026.
- Vanguard Asset Management held 21,659 shares of Rapport Therapeutics worth $728K as of Q3 2026.
- Vanguard Asset Management bought 3,127 Rapport Therapeutics shares in Q3 2026, an estimated $135K.
- Rapport Therapeutics made up ﹤0.01% of Vanguard Asset Management's portfolio in Q3 2026, its #2006 holding.
- Vanguard Asset Management first reported a position in Rapport Therapeutics in Q1 2026 and has held it in 3 quarters since.
- Vanguard Asset Management's Rapport Therapeutics position peaked at $772K in Q2 2026.
- 168 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q3 2026.
Based on Vanguard Asset Management's 13F filing for Q3 2026, filed 13 Nov 2026.